- Home
- WFF vs AKTX Comparison
WFF vs AKTX Comparison
Compare WFF & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFF
- AKTX
- Stock Information
- Founded
- WFF 1984
- AKTX N/A
- Country
- WFF Malaysia
- AKTX United States
- Employees
- WFF N/A
- AKTX 12
- Industry
- WFF Miscellaneous manufacturing industries
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- WFF Consumer Discretionary
- AKTX Health Care
- Exchange
- WFF Nasdaq
- AKTX Nasdaq
- Market Cap
- WFF 18.3M
- AKTX 17.2M
- IPO Year
- WFF 2025
- AKTX N/A
- Fundamental
- Price
- WFF $0.62
- AKTX $0.51
- Analyst Decision
- WFF
- AKTX Strong Buy
- Analyst Count
- WFF 0
- AKTX 2
- Target Price
- WFF N/A
- AKTX $3.30
- AVG Volume (30 Days)
- WFF 60.5K
- AKTX 458.4K
- Earning Date
- WFF 04-30-2026
- AKTX 11-13-2025
- Dividend Yield
- WFF N/A
- AKTX N/A
- EPS Growth
- WFF N/A
- AKTX N/A
- EPS
- WFF 0.00
- AKTX N/A
- Revenue
- WFF $4,572,290.00
- AKTX N/A
- Revenue This Year
- WFF N/A
- AKTX N/A
- Revenue Next Year
- WFF N/A
- AKTX N/A
- P/E Ratio
- WFF $115.59
- AKTX N/A
- Revenue Growth
- WFF N/A
- AKTX N/A
- 52 Week Low
- WFF $0.45
- AKTX $0.50
- 52 Week High
- WFF $29.26
- AKTX $2.45
- Technical
- Relative Strength Index (RSI)
- WFF N/A
- AKTX 30.19
- Support Level
- WFF N/A
- AKTX $0.60
- Resistance Level
- WFF N/A
- AKTX $0.65
- Average True Range (ATR)
- WFF 0.00
- AKTX 0.07
- MACD
- WFF 0.00
- AKTX -0.02
- Stochastic Oscillator
- WFF 0.00
- AKTX 3.00
About WFF WF Holding Limited Ordinary Shares
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.